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ChemotherapyAbstract The prognosis of metastatic melanoma is poor. Pre-targeted treatment era, the combina-
tion of interferon-a (IF-a) plus chemotherapy had been used and have generally short response
duration. Herein, we present a metastatic melanoma case that achieved long-term durable complete
response (CR) IF-a plus chemotherapy and IF-a maintenance therapy and had lower Regulatory T
(Treg) cells. A ﬁfty-year old woman was admitted to the hospital with metastatic melanoma.
Lactate dehydrogenase (LDH) level was 660 U/L. The percentage of CD4+CD25+ Treg cells
was 2.4% in CD4+ lymphocytes. The IF-a plus chemotherapy and IF-a maintenance were admin-
istered. After six courses of chemotherapy, CR was achieved. Vitiligo and hypothyroidism occurred.
The patient has remained in CR for approximately 7 years until second pleural metastases were
detected and death. The patient has positive prognostic factors such as induction of autoimmunity,
small tumor volume, mild elevated LDH level, and lower Treg cell percentage. She survived long
term with CR after IF-a treatment with concurrent chemotherapy and maintenance. IF-a plus che-
motherapy may be a treatment option for metastatic melanoma in selected cases who cannot reach
new targeted drugs.
ª 2015 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Metastatic melanoma is an aggressive disease with poor prog-
nosis. Median survivals are 6–15 months [1]. Melanoma is less
sensitive to chemotherapy or radiotherapy than other cancers.
Interferon-a (IF-a) treatment is a treatment option and has a
response rate of 16% (one-third complete response) for
advanced melanoma. The median duration of response is
162 B. Karago¨z et al.approximately 4 months. Its combination with chemotherapy
had been frequently used in treatment of metastatic malignant
melanoma until new agents such as Raf kinase inhibitors, Mek
inhibitors and ipilimumab were discovered.
Herein, we present a metastatic melanoma case that
achieved long-term durable complete response (CR) IF-a plus
chemotherapy and IF-a maintenance therapy and had lower
Regulatory T (Treg) cells.
Case report
A ﬁfty-year old woman was admitted to our clinic with
right pleural and multiple skin recurrences of melanoma
(DFS: 28 months). Lactate dehydrogenase (LDH) level was
660 U/L. CD4+ lymphocyte ratio among lymphocytes
was 26.75%. The percentage of CD4+CD25+ Treg cells
was 2.4% in CD4+ lymphocytes (Fig. 1).
The biochemotherapy was administered with dacarbazine
(DTIC) 300 mg/m2, cisplatin 30 mg/m2 days 1–3 every 21 days,
and INF-a2b 5 MU subcutaneously three times a week, then
treatment was maintained with INF-a2b 5 MU three times a
week. After six courses of chemotherapy, complete response
(CR) was achieved. Vitiligo and hypothyroidism occurred.
The patient has remained in CR for approximately 7 years.
Pleural relapse was detected. She deceased after ipilimumab
and vemurafenib treatment.
Discussion
Before the era of new molecular targeted agents, combinations
with biologic agents and chemotherapy have been extensively
investigated for metastatic melanoma. Firstly, addition of
IF-a to DTIC has increased response rate in phase II studies,
but phase III trials failed to conﬁrm survival advantage [2,3].
Thereafter, survival advantage of a combination of CVD (cis-
platin, vinblastine, and DTIC) chemotherapy plus IL-2 and
IF-a has been shown [4]. EORTC 18951 study evaluatedFigure 1 CD4+CD25+ Treg cells in peripheral blood of the
patient.addition of IL-2 to cisplatin, DTIC plus IF-a, however, they
did not show survival advantage [5].
Although biochemotherapy studies did not support survival
beneﬁt, the presented case survived for 7 years in CR after
combination of chemotherapy and IF-a. This duration is
longer than survival data of two large studies (9.1 and
3.9 months). This may be due to IF-a maintenance, although
the effect of biologic agent maintenance has not been well
known. Some predictive factors such as small volume skin or
soft tissue metastases, LDH level, performance status,
hypothyroidism, vitiligo occurence have described for long
term survival [6–8]. Our case had also mild elevated LDH,
good performance status, only skin and soft tissue metastases,
hypothyroidism, and vitiligo.
Treg cells are another prognostic factor of cancer patients.
They have a role in self-tolerance and immune homeostasis
and mediate immunosuppression against tumor. It is reported
that Treg cells increase in peripheral blood and tumor
microenvironment of melanoma patients [9]. Their increase is
associated with poor prognosis in melanoma [9]. Treg cell per-
centage of the patient (2.4% in CD4+ lymphocytes) was lower
than reported range of melanoma patients (4.9–16%) and data
of our previous lung cancer study [10]. This may be one of the
explanations of long durable response. This observation
should be conﬁrmed by prospective clinical trials.
In conclusion, she survived long term in CR after IF-a
treatment with concurrent chemotherapy and maintenance.
The studies showing whether the patients are responsive to
chemoimmunotherapy, are required. IF-a plus chemotherapy
may be a treatment option for metastatic melanoma in selected
cases who cannot reach new targeted drugs.
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